US Capitol Capsule: FDA's 'Trade-Off' Balancing Act: Room For Disease Severity?
This article was originally published in Scrip
Executive Summary
Should the FDA take the severity of a disease into account when weighing the benefits of a new treatment against its risks, especially for the most deadly conditions, such as pancreatic cancer or cirrhosis of the liver?